GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NGNE
The shares of Neurogene, a company developing gene therapy for rare neurological diseases, are a venture bet on its scientific platform. Their price reflects not current revenue, but rather investors' faith in the potential of its developments and clinical trial results.
Share prices of companies in the market segment - Neuro
Neurogene (NGNE) is a biotech company focused on developing gene therapies for rare and severe neurological diseases for which there are no effective treatments. We classify it under the "Neurology" category. The chart below shows the dynamics of this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Neurogene is a biotech company developing gene therapies for rare and severe neurological diseases. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Neurogene compares to it.
Change in the price of a company, segment, and market as a whole per day
NGNE - Daily change in the company's share price NGNE
Shares of Neurogene, a gene therapy company, are extremely volatile. Change_co measures the market's reaction to clinical trial data. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Neurogene Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with NGNE, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Neurogene is a biopharmaceutical company specializing in gene therapy for rare neurological diseases. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Neurogene's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NGNE
Neurogene Inc.'s year-to-date performance is a story of gene therapy development for rare neurological diseases. Its 12-month market cap is entirely dependent on progress in clinical trials. Every report on the safety and potential efficacy of its drugs is a fundamental milestone, shaping investor confidence in its scientific platform.
Annual dynamics of market capitalization of the market segment - Neuro
Neurogene, a recent IPO, is developing gene therapies for rare neurological diseases. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to a sector dominated by giants with established products.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neurogene is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NGNE
Neurogene's value as a gene therapy company will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of its clinical trials for drugs to treat rare neurological diseases, which will determine its future.
Monthly dynamics of market capitalization of the market segment - Neuro
Neurogene is a biotech company developing gene therapies for rare and severe neurological diseases. Its value reflects investors' hopes for future clinical success. The chart below shows the overall sentiment in the cutting-edge neuroscience sector, where the stakes are particularly high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Neurogene Inc. is a clinical-stage biotech company developing gene therapies for rare neurological diseases. Its stock is a classic venture bet. Its performance is entirely dependent on the success or failure of clinical trials and has no connection to broader market movements.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NGNE
Shares of Neurogene, a clinical-stage company developing gene therapy for rare neurological diseases, are extremely volatile. Weekly price movements depend entirely on news about clinical trials and scientific publications. The chart below illustrates how short-term scientific events can cause sharp price fluctuations in biotech stocks.
Weekly dynamics of market capitalization of the market segment - Neuro
How does Neurogene's performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news of its gene therapy, with the overall trend. This helps us understand whether the stock's movement is the result of a unique scientific event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart shows how out of sync its weekly performance is with the broader market. Its stock price is driven solely by clinical trial news, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
NGNE - Market capitalization of the company NGNE
The price chart of Neurogene Inc. reflects investor bets on its gene therapy for treating rare and devastating neurological diseases. This clinical-stage company's market cap reflects the hopes for its scientific platform. The dynamics clearly demonstrate the high volatility and risks inherent in advanced biotechnology.
NGNE - Share of the company's market capitalization NGNE within the market segment - Neuro
Neurogene Inc. is a biotechnology company whose market share is based on its development of gene therapy for the treatment of rare and severe neurological diseases. Its market capitalization reflects the potential and risks of its cutting-edge clinical programs.
Market capitalization of the market segment - Neuro
This chart shows the combined market capitalization of biotech companies developing gene therapies for rare neurological diseases. Neurogene is a pioneer in this complex field. The dynamics on the chart reflect the enormous hopes and risks associated with developing drugs that can cure with a single injection.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart reflects the market value of hope for patients with rare genetic diseases of the nervous system. Neurogene's market cap reflects investors' faith in its gene therapy platform. The line shows how cutting-edge science targeting incurable diseases shapes its value in the global biotechnology industry.
Book value capitalization of the company, segment and market as a whole
NGNE - Book value capitalization of the company NGNE
The book value of clinical-stage Neurogene Inc. is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for gene therapy platforms for rare neurological diseases. The dynamics demonstrate how the company is investing in the development of its core asset—science.
NGNE - Share of the company's book capitalization NGNE within the market segment - Neuro
For Neurogene, a gene therapy developer, its tangible assets include cutting-edge laboratories and, potentially, manufacturing capabilities for creating complex vectors. The chart shows its stake in this nascent scientific and manufacturing infrastructure for treating rare neurological diseases.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Neurogene, which is developing gene therapies for rare neurological diseases, looks like a "lightweight." Its value lies in its scientific platform and patents, not in the large manufacturing plants it has yet to build.
Book value of all companies included in the broad market index - GURU.Markets
Neurogene is a biotech company developing gene therapies for rare neurological diseases. Its assets are not factories, but patents, preclinical data, and a scientific platform. The company's balance sheet is an investment in "reprogramming" biology. Against the backdrop of the material world, Neurogene is trying to correct its most complex "mistakes."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NGNE
Neurogene's balance sheet is its cash and scientific platform. Its market capitalization is a bet on the success of its gene therapy for rare diseases. The MvsBCap_Co chart shows how many times the "hope" of curing a single rare disease could be worth compared to the company's entire balance sheet.
Market to book capitalization ratio in a market segment - Neuro
Neurogene is developing gene therapy for rare neurological diseases. Its value is based entirely on its scientific potential. The chart shows a high speculative valuation from the market, which believes in the success of its clinical developments, many times exceeding its tangible assets.
Market to book capitalization ratio for the market as a whole
Neurogene is a biotech company developing gene therapies for rare and severe neurological diseases. Its value lies in its scientific platform and the potential of its drug candidates. This chart illustrates why investors are willing to pay a premium for breakthrough approaches to treating diseases previously considered incurable.
Debts of the company, segment and market as a whole
NGNE - Company debts NGNE
Neurogene, a biotech company developing gene therapies for rare neurological diseases, uses debt to fund its mission. This chart illustrates how the company raises capital to conduct complex and expensive preclinical and clinical trials. In this industry, debt represents the hope of creating cures for incurable diseases.
Market segment debts - Neuro
Neurogene is a biotech company developing gene therapy for the treatment of rare and severe neurological diseases. Gene therapy is one of the most complex and expensive areas in pharmaceuticals. This chart shows the company's financial position at the clinical stage, when all resources are focused on advancing its breakthrough, but capital-intensive, developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NGNE
Neurogene is a biotech company developing gene therapy for rare neurological diseases. This chart shows its reliance on debt to finance expensive research. For a clinical-stage company, high debt is an extreme risk, dependent entirely on the success of trials and future drug approvals.
Market segment debt to market segment book capitalization - Neuro
Neurogene is a clinical-stage biotech company developing gene therapy for rare neurological diseases. This is a cutting-edge, but extremely expensive, area of medicine. The chart shows how the company's debt load for R&D funding compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Neurogene (NGNE) is a biotech company developing gene therapies for rare neurological diseases. Funding for such cutting-edge research is almost always provided through equity. This chart shows the overall market leverage, clearly illustrating the financial model of a biotech that operates debt-free until drug approval.
P/E of the company, segment and market as a whole
P/E - NGNE
This chart shows the valuation of Neurogene, a biotech company developing gene therapy for rare neurological diseases. There is no price-to-earnings ratio (P/E). The company's value is a pure bet on the success of its scientific research. The chart's dynamics depend entirely on the results of preclinical and clinical trials.
P/E of the market segment - Neuro
This chart illustrates the average P/E ratio for biotech companies involved in gene therapy. For Neurogene, which operates in this complex field, it serves as a backdrop. It shows the overall level of investor faith in this revolutionary but risky technology, providing context for Neurogene's valuation.
P/E of the market as a whole
Neurogene is a biotech company specializing in gene therapy for rare and severe neurological diseases. The company uses cutting-edge technologies to deliver therapeutic genes to the brain. This risk appetite chart helps understand how investors evaluate breakthrough but risky approaches in medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NGNE
Neurogene is a biotechnology company developing gene therapy for the treatment of rare and severe neurological diseases. This chart reflects investor expectations for its cutting-edge scientific developments. The valuation is entirely dependent on confidence in the success of its clinical programs and the potential of gene therapy to address previously intractable medical problems.
%20P%2FE%20NGNE&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NGNE&v=1772565459430 "Chart of the company's future (projected) P/E NGNE")
Future (projected) P/E of the market segment - Neuro
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart reflects the company's long-term profitability expectations compared to other biotech companies. It shows how highly the market values the scientific potential of their developments and the likelihood of their future commercial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772565459476 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Neurogene is developing gene therapy for rare neurological diseases. This is a cutting-edge field of science with high risk and potential. This market expectations chart reflects the overall risk appetite of investors. Market optimism makes it easier for companies like Neurogene to raise the significant capital needed for research and development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772565459511 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NGNE
Neurogene is a biotechnology company developing gene therapies for the treatment of rare and severe neurological diseases. The company is in early-stage clinical trials. Its financial performance reflects significant investments in cutting-edge science. This chart illustrates the long and risky path to creating the drugs of the future.
Profit of companies in the market segment - Neuro
Neurogene is developing gene therapy for rare neurological diseases. Currently in clinical trials, the company embodies the promise and peril of biotechnology. This chart reflects the collective bet of investors on scientific breakthroughs, where the current losses of the entire sector are investments in a future that could radically change medicine.
Overall market profit
Neurogene is a clinical-stage biotech company developing gene therapies for rare neurological diseases. Its future depends solely on the success of clinical trials and scientific breakthroughs. Investors in Neurogene focus on lab data, not the macroeconomic indicators that shape this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NGNE
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart reflects analyst expectations, which are entirely dependent on the success of its clinical programs. Positive trial data could dramatically change these forecasts, as the company does not yet have commercial products.
%20profit%20of%20the%20company%20NGNE&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NGNE&v=1772565459701 "Graph of future (projected) profit of the company NGNE")
Future (predicted) profit of companies in the market segment - Neuro
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart shows the revenue forecast for the entire neuropharmaceutical sector. It reflects general expectations for the success of gene therapy and the market's willingness to pay for innovative treatments. This background is important for assessing the long-term potential of Neurogene's developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772565459732 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Neurogene is a biotech company developing gene therapies for rare neurological diseases. Its future depends entirely on the success of clinical trials and its ability to attract capital. The overall investment climate, which can be assessed from this chart, determines the availability of funding for such long-term and risky scientific projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772565459753 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NGNE
Neurogene is a clinical-stage biotech company focused on developing gene therapies for rare and severe neurological diseases. It has no commercial revenue yet. This chart illustrates how investors evaluate the scientific potential of its developments, betting on future success in one of the most challenging areas of medicine.
P/S market segment - Neuro
Neurogene is a clinical-stage biotech company specializing in developing gene therapies for rare and devastating neurological diseases. Its approach focuses on delivering functional copies of genes to combat disease. This chart shows the average valuation in the sector, helping to understand how the market views Neurogene's scientific platform and potential.
P/S of the market as a whole
Neurogene is a clinical-stage biotech company developing gene therapies for rare and severe neurological diseases that currently lack effective treatments. This cutting-edge science comes with high risk. This market valuation chart helps understand the premium investors are paying for this potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NGNE
Neurogene is a clinical-stage biotech company focused on gene therapy for rare neurological diseases. Without revenue, its value is entirely dependent on future prospects. This chart reflects the market's assessment of the company's scientific potential and the potential future sales of its drugs.
%20P%2FS%20NGNE&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NGNE&v=1772565459981 "The graph of the company's future (projected) P/S NGNE")
Future (projected) P/S of the market segment - Neuro
Neurogene is a biotech company developing gene therapies for the treatment of rare and severe neurological diseases. This chart compares market expectations for its future revenue with those of other neuroscience companies. The valuation reflects investor expectations for the success of its clinical programs and the potential of its platform.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772565460032 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Neurogene is a biotech company developing gene therapies for rare neurological diseases. Its valuation is a bet on future scientific success. Overall market optimism, reflected in this chart, is critical for Neurogene, as it provides access to the capital needed to conduct lengthy and expensive clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772565460044 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NGNE
Neurogene is a clinical-stage biotechnology company developing gene therapies for the treatment of rare and severe neurological diseases. The company's revenue, if any, comes from collaborations and grants, not sales. The chart reflects funding that allows the company to advance its complex and expensive research programs.
Sales of companies in the market segment - Neuro
Neurogene is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of rare neurological diseases. The company currently has no commercial products and is funded through private equity. This chart reflects investor interest in cutting-edge biotechnology, where gene therapy is one of the most promising areas.
Overall market sales
Neurogene is a biotech company developing gene therapies for rare neurological diseases. The company's prospects depend entirely on the success of its research and clinical trials. The connection to this graph is indirect: the overall health of the economy affects the availability of capital for funding long-term and risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NGNE
Neurogene is a biotechnology company developing gene therapies for the treatment of rare and severe neurological diseases. The company is in clinical trials. This chart reflects analysts' confidence in Neurogene's scientific platform and the commercial potential of its drug candidates if they are approved by regulators.
%20sales%20of%20the%20company%20NGNE&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NGNE&v=1772565460327 "Schedule of future (projected) sales of the company NGNE")
Future (projected) sales of companies in the market segment - Neuro
Neurogene is a biotech company developing gene therapies for the treatment of rare and severe neurological diseases. This chart shows the overall outlook for the neuroscience sector. It allows one to assess the prospects of the company's developments and how the success or failure of clinical trials could impact its future within the industry as a whole.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772565460525 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Neurogene Inc. is a biotechnology company developing gene therapies for rare neurological diseases. This chart, reflecting the investment climate in the life sciences sector, is critically important. Neurogene's ability to attract significant capital to conduct complex and lengthy clinical trials directly depends on investor confidence in the future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772565460591 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NGNE
Neurogene is at the forefront of gene therapy, developing treatments for rare and severe neurological diseases. Like many clinical-stage biotech companies, its activities are an investment in science. This chart reflects the significant research costs that come with the opportunity to transform patients' lives.
Market segment marginality - Neuro
Neurogene is a biotech company developing gene therapy for rare and severe neurological diseases. Currently in the clinical stage, the company is actively investing in its research. The data in the chart does not reflect current profits, but rather the scale of investment in a scientific platform that, if successful, could radically change the lives of patients.
Market marginality as a whole
Neurogene is a biotech company developing gene therapy for rare and severe neurological diseases. The overall picture of profitability is irrelevant for them. Their future depends entirely on the success of their research in the clinic. It's a high-risk bet that their technology can transform the lives of patients with devastating diseases.
Employees in the company, segment and market as a whole
Number of employees in the company NGNE
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart shows its small but growing team of scientists. The expansion is a direct indicator of progress in its complex and expensive clinical programs and investments in its own manufacturing.
Share of the company's employees NGNE within the market segment - Neuro
Neurogene is a biotech company developing gene therapies for rare and severe neurological diseases. This chart shows the percentage of leading neurogenetics scientists the company attracts. This demonstrates its focus on cutting-edge research and a team dedicated to developing life-changing treatments.
Number of employees in the market segment - Neuro
Neurogene is a biotech company developing gene therapy for rare and severe neurological diseases. The data in the graph reflects employment in this cutting-edge field of biotech. The growing number of scientists in this niche indicates progress in understanding the genetic basis of diseases and the hope of creating treatments previously considered impossible.
Number of employees in the market as a whole
Neurogene Inc. is a biotechnology company developing gene therapies for the treatment of rare and severe neurological diseases. It is at the forefront of medical science. This graph illustrates the overall employment landscape, with companies like Neurogene representing growth opportunities, creating unique jobs for leading scientists and researchers in the fields of genetics and neuroscience.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NGNE (NGNE)
Neurogene Inc. is a biotech company developing gene therapies for rare neurological diseases. Its valuation is based almost entirely on its scientific potential. This chart demonstrates a model where intellectual capital dominates. A small team of scientists can create technology worth hundreds of millions of dollars, resulting in an extremely high valuation per employee.
%20of%20the%20company%20NGNE%20(NGNE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NGNE-NGNE&v=1772565461188 "Chart of market capitalization per employee (in thousands of dollars) of the company NGNE (NGNE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Neurogene develops gene therapies for rare neurological diseases. In biotech, where science is everything, this metric reflects investors' faith in the potential of the R&D platform. The chart shows how much future value the market attributes to the work of each company scientist, compared to the industry average.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772565461315 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Neurogene is a biotech company developing gene therapies for rare neurological diseases. Its value is based entirely on its scientific potential. This chart shows a high market value per employee, which reflects not current operations but investor expectations that its research will lead to breakthrough treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772565461404 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NGNE (NGNE)
Neurogene (NGNE) is an R&D-stage biopharmaceutical company developing gene therapies for rare neurological diseases. This is one of the most complex areas of science. This chart shows the "cost" of this research—the negative profit (expense) for each scientist working on drugs that can cost millions of dollars per dose.
%20Chart%20NGNE%20(NGNE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NGNE-NGNE&v=1772565461452 "Company Profit Per Employee (in thousands of dollars) Chart NGNE (NGNE)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Neurogene is a biotech company focused on developing gene therapies for the treatment of rare and severe neurological diseases in children. This chart demonstrates the benchmark for staff efficiency in the biotech industry. It is important for assessing how effectively Neurogene's scientific team utilizes investor capital to advance its research.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772565461548 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Neurogene is a clinical-stage biotech company focused on gene therapy for rare neurological diseases. Like other R&D biotechs, this chart isn't about profit, but about investment. It shows the amount of capital (received from investors) spent on each scientist and employee to advance their complex treatments through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772565461596 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NGNE (NGNE)
Neurogene is a biotech company developing gene therapies for rare neurological diseases. This chart reflects its focus on science. Zero revenue per employee is normal for a company in the preclinical or early clinical stage. All value is generated in R&D and will only be realized once the therapy is approved.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NGNE-NGNE&v=1772565461623 "Sales chart per company employee NGNE (NGNE)")
Sales per employee in the market segment - Neuro
Neurogene (NGNE) is a clinical-stage biotech company specializing in gene therapy for rare and severe neurological diseases. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform in one of the most complex areas of medicine.
Sales per employee for the market as a whole
Neurogene Inc. is a clinical-stage biotech company focused on gene therapy for rare neurological diseases. The company currently has no commercial products. This graph is close to zero. It reflects current investment in R&D: a staff of highly qualified scientists is working to develop breakthrough treatments, and investors are anticipating future returns.
Short shares by company, segment and market as a whole
Shares shorted by company NGNE (NGNE)
Neurogene is a clinical-stage biotech developing gene therapies for rare neurological diseases. This chart shows bearish bets. Shorting gene therapy biotechs is betting on huge risks: trial failures, safety issues, or FDA denial of approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NGNE-NGNE&v=1772565461718 "Short Shares Chart for the Company NGNE (NGNE)")
Shares shorted by market segment - Neuro
Neurogene (NGNE) is a clinical-stage biotech company developing gene therapies for rare and severe neurological diseases. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Neurogene, which operates in a complex field, this signals a "venture drought" for funding trials.
Shares shorted by the overall market
Neurogene (NGNE) is a clinical-stage biotech developing gene therapies for rare neurological diseases. It's an extremely risky bet on science. This market pessimism chart shows when investors are risk-averse. NGNE shares, lacking revenue, come under intense pressure at such times.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NGNE (NGNE)
Neurogene is a clinical-stage biotech company working on gene therapy for rare neurological diseases. This chart measures pure speculative hope. It shows when the stock is "overbought" on the slightest positive signal from the lab or "oversold" amid a long R&D cycle.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NGNE-NGNE&v=1772565461859 "RSI 14 indicator chart for the company's stock NGNE (NGNE)")
RSI 14 Market Segment - Neuro
Neurogene is a biotech company specializing in developing gene therapies for the treatment of rare and severe neurological diseases. This chart measures the collective excitement in the gene therapy sector. It helps us understand whether the entire speculative segment is overheated by expectations of clinical success.
RSI 14 for the overall market
Neurogene, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like NGNE are forced to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NGNE (NGNE)
Neurogene is a biotech company developing gene therapies for the treatment of rare and severe neurological diseases in children. This chart shows the average target price. Analysts' forecasts are based on clinical data, approval probability, and the potential market size for these highly complex treatments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NGNE-NGNE&v=1772565462055 "A chart showing analyst consensus forecasts for the expected stock price. NGNE (NGNE)")
The difference between the consensus estimate and the actual stock price NGNE (NGNE)
Neurogene (NGNE) is a clinical-stage biotech developing gene therapies for rare and severe neurological diseases (Rett syndrome). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NGNE-NGNE&v=1772565462099 "A chart showing the difference between the consensus forecast and the actual stock price. NGNE (NGNE)")
Analyst consensus forecast for stock prices by market segment - Neuro
Neurogene is a biotech company developing gene therapy for the treatment of rare and devastating neurological diseases in children (Rett syndrome). This chart shows the overall expectations of analysts in the neuroscience sector. It reflects whether experts believe breakthroughs in the treatment of complex genetic diseases are possible.
Analysts' consensus forecast for the overall market share price
Neurogene is a clinical-stage biotech company specializing in developing gene therapies for rare and severe neurological diseases. This chart shows the overall "risk appetite." For Neurogene, a company working at the forefront of science, overall market optimism (a rising chart) is critical to attracting the capital needed to fund lengthy and expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NGNE
Neurogene is a clinical-stage biotech company specializing in gene therapy for rare and devastating pediatric neurological diseases. It's a high-risk bet on breakthrough science. This chart is purely an indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Neuro
Neurogene is a clinical-stage biotech company developing gene therapies for rare neurological diseases. It's a high-risk, high-potential business. This chart shows the average index for the neurosegment. It provides a benchmark for how Neurogene's performance compares to the sector average for companies pursuing scientific breakthroughs.
The AKIM Index for the overall market
Neurogene is a biotech company developing genetic drugs to treat rare and devastating neurological diseases. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding innovative scientific companies like Neurogene.
